TP53 and neoplasm: Except for clinical trials, a dual inhibitor for PI3K and HDAC termed BEBT-908 was developed to facilitate tumor ferroptosis by hyperacetylating p53 and upregulating the endogenous expression of MHC-I in tumor cells [320].